Literature DB >> 33922643

ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca2+ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIδ.

Mario G Pavez-Giani1, Pablo I Sánchez-Aguilera1, Nils Bomer1, Shigeki Miyamoto2, Harmen G Booij1, Paula Giraldo1, Silke U Oberdorf-Maass1, Kirsten T Nijholt1, Salva R Yurista1, Hendrik Milting3, Peter van der Meer1, Rudolf A de Boer1, Joan Heller Brown2, Herman W H Sillje1, B Daan Westenbrink1.   

Abstract

ATPase inhibitory factor-1 (IF1) preserves cellular ATP under conditions of respiratory collapse, yet the function of IF1 under normal respiring conditions is unresolved. We tested the hypothesis that IF1 promotes mitochondrial dysfunction and pathological cardiomyocyte hypertrophy in the context of heart failure (HF). Methods and results: Cardiac expression of IF1 was increased in mice and in humans with HF, downstream of neurohumoral signaling pathways and in patterns that resembled the fetal-like gene program. Adenoviral expression of wild-type IF1 in primary cardiomyocytes resulted in pathological hypertrophy and metabolic remodeling as evidenced by enhanced mitochondrial oxidative stress, reduced mitochondrial respiratory capacity, and the augmentation of extramitochondrial glycolysis. Similar perturbations were observed with an IF1 mutant incapable of binding to ATP synthase (E55A mutation), an indication that these effects occurred independent of binding to ATP synthase. Instead, IF1 promoted mitochondrial fragmentation and compromised mitochondrial Ca2+ handling, which resulted in sarcoplasmic reticulum Ca2+ overloading. The effects of IF1 on Ca2+ handling were associated with the cytosolic activation of calcium-calmodulin kinase II (CaMKII) and inhibition of CaMKII or co-expression of catalytically dead CaMKIIδC was sufficient to prevent IF1 induced pathological hypertrophy. Conclusions: IF1 represents a novel member of the fetal-like gene program that contributes to mitochondrial dysfunction and pathological cardiac remodeling in HF. Furthermore, we present evidence for a novel, ATP-synthase-independent, role for IF1 in mitochondrial Ca2+ handling and mitochondrial-to-nuclear crosstalk involving CaMKII.

Entities:  

Keywords:  CaMKII; calcium handling; cardiomyocyte hypertrophy; heart failure; mitochondria

Year:  2021        PMID: 33922643     DOI: 10.3390/ijms22094427

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  40 in total

1.  DRP-1-mediated mitochondrial fragmentation during EGL-1-induced cell death in C. elegans.

Authors:  Ravi Jagasia; Phillip Grote; Benedikt Westermann; Barbara Conradt
Journal:  Nature       Date:  2005-02-17       Impact factor: 49.962

2.  Regulation of mitochondrial structure and function by the F1Fo-ATPase inhibitor protein, IF1.

Authors:  Michelangelo Campanella; Edward Casswell; Stephanie Chong; Ziad Farah; Mariusz R Wieckowski; Andrey Y Abramov; Andrew Tinker; Michael R Duchen
Journal:  Cell Metab       Date:  2008-07       Impact factor: 27.287

3.  Extrinsic conditions influence the self-association and structure of IF1, the regulatory protein of mitochondrial ATP synthase.

Authors:  Vytaute Boreikaite; Basile I M Wicky; Ian N Watt; Jane Clarke; John E Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-07       Impact factor: 11.205

Review 4.  The cell biology of mitochondrial membrane dynamics.

Authors:  Marta Giacomello; Aswin Pyakurel; Christina Glytsou; Luca Scorrano
Journal:  Nat Rev Mol Cell Biol       Date:  2020-02-18       Impact factor: 94.444

5.  Knockout of the ATPase inhibitory factor 1 protects the heart from pressure overload-induced cardiac hypertrophy.

Authors:  Kevin Yang; Qinqiang Long; Kamalamma Saja; Fengyuan Huang; Steven M Pogwizd; Lufang Zhou; Masasuke Yoshida; Qinglin Yang
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

Review 6.  Expert consensus document: Mitochondrial function as a therapeutic target in heart failure.

Authors:  David A Brown; Justin B Perry; Mitchell E Allen; Hani N Sabbah; Brian L Stauffer; Saame Raza Shaikh; John G F Cleland; Wilson S Colucci; Javed Butler; Adriaan A Voors; Stefan D Anker; Bertram Pitt; Burkert Pieske; Gerasimos Filippatos; Stephen J Greene; Mihai Gheorghiade
Journal:  Nat Rev Cardiol       Date:  2016-12-22       Impact factor: 32.419

7.  Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure.

Authors:  Salva R Yurista; Timothy R Matsuura; Herman H W Silljé; Kirsten T Nijholt; Kendra S McDaid; Swapnil V Shewale; Teresa C Leone; John C Newman; Eric Verdin; Dirk J van Veldhuisen; Rudolf A de Boer; Daniel P Kelly; B Daan Westenbrink
Journal:  Circ Heart Fail       Date:  2020-12-28       Impact factor: 8.790

8.  Acute inhibition of excessive mitochondrial fission after myocardial infarction prevents long-term cardiac dysfunction.

Authors:  Marie-Hélène Disatnik; Julio C B Ferreira; Juliane Cruz Campos; Kátia Sampaio Gomes; Paulo M M Dourado; Xin Qi; Daria Mochly-Rosen
Journal:  J Am Heart Assoc       Date:  2013-10-08       Impact factor: 5.501

Review 9.  A Review of the Inhibition of the Mitochondrial ATP Synthase by IF1 in vivo: Reprogramming Energy Metabolism and Inducing Mitohormesis.

Authors:  Ana García-Aguilar; José M Cuezva
Journal:  Front Physiol       Date:  2018-09-19       Impact factor: 4.566

10.  NH-sulfoximine: A novel pharmacological inhibitor of the mitochondrial F1 Fo -ATPase, which suppresses viability of cancerous cells.

Authors:  Daniela Strobbe; Rosalba Pecorari; Oriana Conte; Antonella Minutolo; Christine M M Hendriks; Stefan Wiezorek; Danilo Faccenda; Rosella Abeti; Carla Montesano; Carsten Bolm; Michelangelo Campanella
Journal:  Br J Pharmacol       Date:  2020-12-14       Impact factor: 9.473

View more
  5 in total

1.  Trans-cinnamaldehyde protects against phenylephrine-induced cardiomyocyte hypertrophy through the CaMKII/ERK pathway.

Authors:  Dongdong Qian; Jing Tian; Sining Wang; Xiaoli Shan; Pei Zhao; Huihua Chen; Ming Xu; Wei Guo; Chen Zhang; Rong Lu
Journal:  BMC Complement Med Ther       Date:  2022-04-25

Review 2.  Involvement of Oxidative Stress in the Development of Subcellular Defects and Heart Disease.

Authors:  Naranjan S Dhalla; Vijayan Elimban; Monika Bartekova; Adriana Adameova
Journal:  Biomedicines       Date:  2022-02-07

3.  Unilateral Acute Renal Ischemia-Reperfusion Injury Induces Cardiac Dysfunction through Intracellular Calcium Mishandling.

Authors:  Carolina Victoria Cruz Junho; Laura González-Lafuente; José Alberto Navarro-García; Elena Rodríguez-Sánchez; Marcela Sorelli Carneiro-Ramos; Gema Ruiz-Hurtado
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

4.  Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation.

Authors:  Tim R Eijgenraam; Nienke M Stege; Vivian Oliveira Nunes Teixeira; Remco de Brouwer; Elisabeth M Schouten; Niels Grote Beverborg; Liu Sun; Daniela Später; Ralph Knöll; Kenny M Hansson; Carl Amilon; David Janzén; Steve T Yeh; Adam E Mullick; Peter van der Meer; Rudolf A de Boer; Herman H W Silljé
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

Review 5.  The Multifaceted ATPase Inhibitory Factor 1 (IF1) in Energy Metabolism Reprogramming and Mitochondrial Dysfunction: A New Player in Age-Associated Disorders?

Authors:  Emilia Gore; Thibaut Duparc; Annelise Genoux; Bertrand Perret; Souad Najib; Laurent O Martinez
Journal:  Antioxid Redox Signal       Date:  2022-01-04       Impact factor: 7.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.